Lymphoma Hub
By Scientific Education Support
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Scientific Education Support
Category: Education
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 3
Reviews: 0
Episodes: 50
Description
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
| Episode | Date |
|---|---|
|
EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?
|
Jul 21, 2026 |
|
EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?
|
Jul 16, 2026 |
|
Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
|
Jul 10, 2026 |
|
EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?
|
Jul 01, 2026 |
|
Annual oncology meeting | Key highlights in lymphoma
|
Jun 22, 2026 |
|
EHA 2026 | What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in CLL?
|
Jun 17, 2026 |
|
ASH 2025 | Key highlights in lymphoma and CLL
|
Dec 22, 2025 |
|
ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL
|
Dec 18, 2025 |
|
What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL?
|
Dec 17, 2025 |
|
ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL
|
Dec 11, 2025 |
|
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
|
Dec 10, 2025 |
|
ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity
|
Dec 10, 2025 |
|
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
|
Dec 05, 2025 |
|
What factors influence BTKi + BCL-2i treatment selection for patients with CLL?
|
Nov 05, 2025 |
|
Latest updates from the phase III STARGLO trial: 2L and 3L+ data
|
Oct 15, 2025 |
|
Symposium | Customizing therapy for MCL: Q&A
|
Sep 04, 2025 |
|
Symposium | Current therapies for MCL and their combinations
|
Sep 03, 2025 |
|
Symposium | Sequencing therapies and practical management of adverse events in MCL
|
Aug 19, 2025 |
|
Symposium | Unmet needs in the treatment of MCL
|
Jul 17, 2025 |
|
Anti-CD19 monoclonal antibodies for the treatment of DLBCL
|
Jul 08, 2025 |
|
CELMoDs for the treatment of non-Hodgkin lymphoma
|
Jul 03, 2025 |
|
ICML 2025 | What do the initial results from the LOTIS-7 trial suggest for loncastuximab tesirine plus glofitamab in R/R DLBCL?
|
Jun 30, 2025 |
|
What is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL?
|
Jun 19, 2025 |
|
EHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL?
|
Jun 18, 2025 |
|
EHA 2025 | How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are eligible for ASCT?
|
Jun 17, 2025 |
|
Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL
|
Jun 02, 2025 |
|
How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?
|
May 30, 2025 |
|
inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
|
Apr 01, 2025 |
|
Symposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphoma
|
Aug 12, 2024 |
|
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
|
Aug 12, 2024 |
|
SYMPHONY 1: A trial update
|
Jan 09, 2023 |
|
Novel therapies in chronic lymphocytic leukemia: An update.
|
Jan 05, 2023 |
|
What are the CAR T-cell therapies on the horizon for lymphoma?
|
Jan 03, 2023 |
|
How do you choose among different BTK inhibitors for treating CLL?
|
Dec 02, 2022 |
|
What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?
|
Nov 07, 2022 |
|
ASCT in DLBCL – is it over?
|
Aug 03, 2022 |
|
What is on the horizon for the frontline treatment of MCL?
|
Jul 25, 2022 |
|
Is frontline R-CHOP still the standard of care for DLBCL?
|
Aug 18, 2021 |
|
What are the recent advances in antibody-drug conjugates for lymphoma treatment?
|
Jul 19, 2021 |
|
What is the role of genetic classification in the diagnosis of DLBCL?
|
Jul 07, 2021 |
|
What factors should be considered when deciding whether to refer a patient for CAR T-cell therapy?
|
Jun 30, 2021 |
|
What does real-world data tell us about frontline treatment strategies for MCL?
|
Jun 29, 2021 |
|
Can ctDNA help inform on the suitability of auto-SCT in patients with DLBCL?
|
Feb 01, 2021 |
|
Why should we use ctDNA assessments in lymphoma diagnostics in the future?
|
Jan 11, 2021 |
|
Does ctDNA add value to current prognostic markers for identifying high-risk patients?
|
Jan 07, 2021 |
|
Is there a role for PET-CT-directed therapy in DLBCL?
|
Dec 17, 2020 |
|
Can we eliminate auto-SCT for patients with MCL?
|
Nov 11, 2020 |
|
Can we avoid chemotherapy entirely in follicular lymphoma?
|
Nov 09, 2020 |
|
An update in CLL from EHA 2020
|
Jul 14, 2020 |
|
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
|
Jun 17, 2020 |